Related Experiment Video

Updated: Jul 31, 2026

In Vitro Colony Assays for Characterizing Tri-potent Progenitor Cells Isolated from the Adult Murine Pancreas
09:31

In Vitro Colony Assays for Characterizing Tri-potent Progenitor Cells Isolated from the Adult Murine Pancreas

Published on: June 10, 2016

Potent beta-cell protection in vitro by an isoquinolinone-derived PARP inhibitor

V Burkart1, K Blaeser, H Kolb

  • 1German Diabetes Research Institute at the University of Düsseldorf.

Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme
|February 11, 2000
PubMed

Insights

A novel PARP inhibitor, PD128763, offers superior protection against beta-cell death compared to nicotinamide. This compound enhances beta-cell resistance to inflammatory attacks more effectively and with longer-lasting effects.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Pharmacology

Background:

  • Poly(ADP-ribose)polymerase (PARP) activation is crucial in beta-cell death induced by DNA damage.
  • Nicotinamide, a B vitamin, protects beta-cells by inhibiting PARP activity.

Purpose of the Study:

  • To evaluate the efficacy of a specific PARP inhibitor, PD128763, in protecting beta-cells from death.
  • To compare the protective effects and duration of action of PD128763 with nicotinamide.

Main Methods:

  • In vitro exposure of islet cells to nitric oxide, oxygen radical generators, and streptozotocin.
  • Assessment of beta-cell protection and cell death following treatment with PD128763 and nicotinamide.
  • Evaluation of the duration of protective effects after compound removal.

Main Results:

  • PD128763 protected islet cells from death at concentrations 100 times lower than nicotinamide.
  • The protective effects of PD128763 were more long-lasting than those of nicotinamide.
  • Neither compound effectively rescued already damaged islet cells from lysis.

Conclusions:

  • PD128763 is a more potent and durable beta-cell protective agent than nicotinamide.
  • PD128763 enhances beta-cell resistance to inflammatory attacks, offering a potential therapeutic advantage.

More Related Videos

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform09:35

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform

Published on: July 16, 2016

Isolated Pancreatic Islet Treatment and Apoptosis Measurement09:36

Isolated Pancreatic Islet Treatment and Apoptosis Measurement

Published on: May 2, 2025

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...